(Circulation. 1996;94:614-621.)
© 1996 American Heart Association, Inc.
Articles |
Effects of Cigarette Smoking on the Angiographic Evolution of Coronary Atherosclerosis
A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy
the Division of Cardiology, Hartford Hospital, Hartford, Conn.
Correspondence to David Waters, MD, Division of Cardiology, Hartford Hospital, 80 Seymour St, Hartford, CT 06102-5037.
Background Although smoking increases both the risk of developing coronary disease and the risk of coronary events in patients with known coronary atherosclerosis, the effect of smoking on the evolution of coronary atherosclerosis as assessed by serial angiography is poorly defined.
Methods and Results Ninety smokers with coronary atherosclerosis shown on a recent angiogram and with fasting cholesterol levels between 220 and 300 mg/dL were enrolled in a randomized, double-blind, placebo-controlled trial of cholesterol-lowering therapy, along with 241 nonsmokers and ex-smokers. Lovastatin at a mean dose of 36 mg/d lowered total and LDL cholesterol by 21±11% and 29±11%, respectively, but these levels changed by <2% in placebo-treated patients. Coronary arteriography was repeated after 2 years in 72 smokers and their 557 lesions were measured blindly with an automated quantitative system, along with 1752 lesions in 227 nonsmokers. Coronary change score, the per-patient mean of the minimal lumen diameter changes for all qualifying lesions, worsened by 0.16±0.16 mm in smokers and by 0.07±0.15 mm in nonsmokers in the placebo group (P<.001). Lovastatin-treated smokers had less worsening (0.07±0.15 mm) than placebo-treated smokers (P=.024). One or more coronary lesions progressed in 16 of 34 lovastatin-treated smokers and in 28 of 38 placebo-treated smokers (47% versus 74%, P<.001). In the placebo group, new coronary lesions developed in 21 of 38 smokers and in 28 of 115 nonsmokers (55% versus 24%, P<.001); fewer lovastatin-treated smokers developed new lesions (15% versus 55%, P<.001).
Conclusions Smoking accelerates coronary progression and new lesion formation as assessed by serial quantitative coronary arteriography. Lovastatin slows the progression of coronary atherosclerosis and prevents the development of new coronary lesions in smokers.
Key Words: atherosclerosis • smoking • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  T. S. Perlstein and R. T. Lee Smoking, Metalloproteinases, and Vascular Disease Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 250 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Freedland, R. M. Carney, and J. A. Skala Depression and Smoking in Coronary Heart Disease Psychosom Med, May 1, 2005; 67(Supplement_1): S42 - S46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Gluckman, M. Sachdev, S. P. Schulman, and R. S. Blumenthal A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, January 19, 2005; 293(3): 349 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Gluckman, B. Baranowski, M. D. Ashen, C. A. Henrikson, M. McAllister, J. B. Braunstein, and R. S. Blumenthal A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction Arch Intern Med, July 26, 2004; 164(14): 1490 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ambrose and R. S. Barua The pathophysiology of cigarette smoking and cardiovascular disease: An update J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1731 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zitzmann, M. Brune, B. Kornmann, J. Gromoll, S. von Eckardstein, A. von Eckardstein, and E. Nieschlag The CAG Repeat Polymorphism in the AR Gene Affects High Density Lipoprotein Cholesterol and Arterial Vasoreactivity J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4867 - 4873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. van Domburg, K. Meeter, D. F. M. van Berkel, R. F. Veldkamp, L. A. van Herwerden, and A. J. J. C. Bogers Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study J. Am. Coll. Cardiol., September 1, 2000; 36(3): 878 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pelkonen, H. Tukiainen, M. Tervahauta, I.-L. Notkola, S.-L. Kivelä, Y. Salorinne, and A. Nissinen Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men Thorax, September 1, 2000; 55(9): 746 - 750. [Abstract] [Full Text]
|
|
|
|
|
|
S. D. Ross, I. E. Allen, J. E. Connelly, B. M. Korenblat, M. E. Smith, D. Bishop, and D. Luo Clinical Outcomes in Statin Treatment Trials: A Meta-analysis Arch Intern Med, August 9, 1999; 159(15): 1793 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Werner and T. A. Pearson What's So Passive About Passive Smoking?: Secondhand Smoke as a Cause of Atherosclerotic Disease JAMA, January 14, 1998; 279(2): 157 - 158. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hasdai, K. N. Garratt, D. E. Grill, A. Lerman, and D. R. Holmes Effect of Smoking Status on the Long-Term Outcome after Successful Percutaneous Coronary Revascularization N. Engl. J. Med., March 13, 1997; 336(11): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 CHOLESTEROL REDUCTION LOWERS CORONARY RISK IN SMOKERS Journal Watch (General), September 3, 1996; 1996(903): 4 - 4. [Full Text]
|
|
|
|
 |
|
 S. A. Glantz and W. W. Parmley Passive and Active Smoking: A Problem for Adults Circulation, August 15, 1996; 94(4): 596 - 598. [Full Text]
|
|